Related Experiment Video
Updated: Jun 24, 2026
11:17
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
Cefpodoxime: pharmacokinetics and therapeutic uses
Krishan Chugh1, Shruti Agrawal
1Sir Ganga Ram Hospital, Rajinder Nagar, New Delhi-110060.
Indian Journal of Pediatrics
|June 6, 2003
Summary
Cefpodoxime proxetil, an oral third-generation cephalosporin, effectively treats various bacterial infections, including respiratory and skin infections. This safe and effective antibiotic requires dose adjustment for kidney impairment and offers convenient twice-daily dosing.
Area of Science:
- Pharmacology
- Infectious Diseases
- Microbiology
Background:
- Cefpodoxime is a third-generation cephalosporin antibiotic.
- Administered as the prodrug cefpodoxime proxetil for enhanced oral absorption.
- Achieves adequate therapeutic concentrations in body fluids, exceeding the minimum inhibitory concentration (MIC).
Purpose of the Study:
- To evaluate the efficacy and safety of cefpodoxime proxetil.
- To determine appropriate dosing and treatment durations for various infections.
- To assess its utility as a step-down therapy from parenteral cephalosporins.
Main Methods:
- Review of pharmacokinetic and pharmacodynamic properties.
- Analysis of clinical data on efficacy against common Gram-positive and Gram-negative bacteria.
- Evaluation of safety profile and side effect incidence.
- Assessment of dosing regimens and treatment outcomes for different infections.
Main Results:
- Cefpodoxime exhibits broad-spectrum activity against common respiratory and skin pathogens, including Staphylococcus, Streptococcus, E. coli, and Klebsiella.
- Effective in treating upper and lower respiratory tract infections, sinusitis, otitis media, skin, and soft tissue infections, and urinary tract infections.
- Demonstrated safety and efficacy in short-course (5-day) treatment regimens compared to 10-day courses.
Conclusions:
- Cefpodoxime proxetil is a safe, effective, and convenient oral antibiotic for various infections.
- Its favorable pharmacokinetic profile and broad spectrum of activity make it a valuable therapeutic option.
- Dosing requires adjustment in patients with renal impairment.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
01:23Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life.
01:27Pharmacodynamic Models: Overview
Pharmacodynamic (PD) responses describe the interaction between a drug and its biological target, culminating in a physiological effect. These responses can be classified into different types: continuous variables, such as blood glucose levels; categorical outcomes, like survival rates; and time-to-event metrics, such as disease progression. Understanding and modeling PD responses are critical for optimizing drug efficacy and safety.PD models describe the relationship between drug concentration...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:28Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...